Neoadjuvant bevacizumab (B) and trastuzumab (T) in combination with weekly paclitaxel (P) as neoadjuvant treatment in HER2-positive breast cancer: Results from a phase II trial (AVANTHER)

被引：0
|
作者：
Fernandez Abad, Maria
Calvo, Isabel
Martinez, Noelia
Herrero, Mercedes
Quijano, Yolanda
Duran, Hipolito
Garcia Aranda, Mariola
Suarez, Ana
Lopez-Rios, Fernando
Perez, Diego
Perea, Sofia
Hidalgo, Manuel
Garca-Estevez, Laura
机构：
[1] Ctr Integral Oncol Clara Campal, Madrid, Spain
[2] Hosp Ramon & Cajal, E-28034 Madrid, Spain
[3] Hosp Costa Sol, Marbella, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
602
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer
    Lin, N. U.
    Seah, D. S.
    Gelman, R.
    Desantis, S.
    Mayer, E. L.
    Isakoff, S.
    DiPiro, P.
    Krop, I. E.
    Come, S. E.
    Weckstein, D.
    Winer, E. P.
    Burstein, H. J.
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 139 (02) : 403 - 410
  • [22] A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer
    N. U. Lin
    D. S. Seah
    R. Gelman
    S. Desantis
    E. L. Mayer
    S. Isakoff
    P. DiPiro
    I. E. Krop
    S. E. Come
    D. Weckstein
    E. P. Winer
    H. J. Burstein
    Breast Cancer Research and Treatment, 2013, 139 : 403 - 410
  • [23] Effect of a combination of pertuzumab, trastuzumab, and weekly paclitaxel on pCR rates and side-effect profile as a neoadjuvant treatment regimen for HER2-positive breast cancer.
    Gupta, Niraj K.
    Giblin, Erica
    Leagre, Christopher A.
    Govert, Kristen
    Givens, Stanley
    Chichester, Tiffany
    Locker, Matthew
    Bhayani, Parin
    Burnett, Riesa
    Spivey, Tara
    Cohen, Stephanie
    Paul, Robert
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [24] Anthracycline, taxane, and trastuzumab-based neoadjuvant chemotherapy in HER2-positive early breast cancer: phase II trial
    Conte, Benedetta
    Montemurro, Filippo
    Levaggi, Alessia
    Blondeaux, Eva
    Molinelli, Chiara
    Cardinali, Barbara
    Poggio, Francesca
    Buzzatti, Giulia
    Bighin, Claudia
    Lambertini, Matteo
    Del Mastro, Lucia
    TUMORI JOURNAL, 2023, 109 (01): : 71 - 78
  • [25] Docetaxel, carboplatin and weekly trastuzumab are active as neoadjuvant therapy in operable HER2-positive breast cancer
    Kolberg, H. -C.
    Akpolat-Basci, L.
    Otterbach, F.
    Drumm, A.
    Tirier, C.
    BREAST, 2011, 20 : S74 - S74
  • [26] Combined neoadjuvant weekly paclitaxel and trastuzumab for HER2-overexpressing breast cancer
    Horiguchi, J.
    Koibuchi, Y.
    Rokutanda, N.
    Nagaoka, R.
    Kikuchi, M.
    Sato, A.
    Ishikawa, Y.
    Odawara, H.
    Iino, Y.
    Takeyoshi, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [27] Paclitaxel, Carboplatin, and Trastuzumab in a Neoadjuvant Regimen for HER2-Positive Breast Cancer: The TRAIN Study.
    Sonke, G. S.
    Mandjes, I. A.
    Holtkamp, M.
    Schot, M.
    Oosterkamp, H. M.
    Wesseling, J.
    Vrancken, Peeters M-J T.
    Rodenhuis, S.
    Linn, S. C.
    CANCER RESEARCH, 2011, 71
  • [28] A randomized trial of trastuzumab deruxtecan and biologydriven selection of neoadjuvant treatment for HER2-positive breast cancer (ARIADNE)
    Foukakis, T.
    Naume, B.
    Karakatsanis, A.
    Andersson, A.
    Barnekow, E.
    Kessler, L. Edman
    Einbeigi, Z.
    Engebraten, O.
    Killander, F.
    Linderholm, B. K.
    Schiza, A.
    Valachis, A.
    Bergh, J.
    Villacampa, G.
    Zouzos, A.
    Hellstrom, M.
    Hartman, J.
    Matikas, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S356 - S356
  • [29] Weekly paclitaxel, pertuzumab and trastuzumab (TPH) neoadjuvant therapy for HER2 positive inflammatory breast cancer
    Overmoyer, Beth
    Regan, Meredith
    Hu, Jiani
    Nakhlis, Faina
    Dominici, Laura
    Lin, Nancy U.
    Freedman, Rachel
    Morganstern, Daniel E.
    Partridge, Ann H.
    Schlosnagle, Emily J.
    Hirshfield-Bartek, Judi
    Bellon, Jennifer
    Morikawa, Aki
    Harrison, Beth T.
    Winer, Eric
    CANCER RESEARCH, 2018, 78 (04)
  • [30] Phase II study of pyrotinib plus albumin-bound paclitaxel and trastuzumab as neoadjuvant treatment in HER2-positive early or locally advanced breast cancer
    Luo, T.
    Zhong, X.
    He, P.
    Yan, X.
    Tian, T.
    Wei, B.
    Zhang, Z.
    Li, J.
    Zheng, H.
    ANNALS OF ONCOLOGY, 2020, 31 : S331 - S331
12345